animal health

/Tag:animal health
­

Bionaturis Group gets patent approval in India

Bionaturis Group has received notification from the patent office of India of the approval of the patent entitled “Production of biologically active proteins”, contributing to the protection of this patent family, already approved in the main European markets, USA, China, Mexico, Canada, and Australia.

Specifically, this patent family protects the production and use, within the pharmacological field, of ZERA-based microparticles, a self-assembling sequence developed by ZIP. These microparticles have demonstrated efficacy as second-generation vaccines, being able to develop a higher immune response than the same antigen in soluble form and without using of additional adjuvants. ZERA VACCINES are currently being evaluated by leading companies in the veterinary sector in order to formalize licensing agreements.
Zera Vaccines is part of the technological portfolio of the CDMO division of the biotechnological group, provided by ZIP Solutions, a specialist in bioprocesses at industrial scale.

Bionaturis Group, which is integrating businesses with ADL Biopharma, has received up to four patent approvals year to date, strengthening the protection of its high-tech premium portfolio. Please, click here to read the Relevant Information (only in Spanish)
 

April 11th, 2018|Hechos Relevantes|Comments Off on Bionaturis Group gets patent approval in India

Zip patent of Bionaturis Group granted in Australia

ZIP Solutions is a biotechnological company devoted to develop and commercialise innovative solutions for industrial and pharmaceutical applications. The company has an in-depth knowledge of the requirements of the human and animal health industry, and offers its proprietary solutions, Zera® and Splittera, as differentiating and highly competitive tools to meet their demanding needs. 

 

These patents are of special relevance for Bionaturis group since Splittera is subject of a worldwide exclusive licensing agreement with a top leading multinational company, for its commercialization in the industrial purification of biological products. The agreement contemplates upfront, milestone-payments and royalties for sales. This agreement is a proof of principle of the usefulness and added value of Splittera for the biopharmaceutical sector, which presents a global expected market figure worth of 236 billion dollars by 2019.
Splittera is part of the technological portfolio of the CDMO division of the biotechnological group, provided by ZIP Solutions, a specialist in industrial bioprocessing.

To read the Relevant Information (only in Spanish) click here.

About Bionaturis

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).

 

 

March 8th, 2018|Blog english|Comments Off on Zip patent of Bionaturis Group granted in Australia

Fran Bascón tells us about VIV-MEA 2018,Abu Dhabi.

         Last 5th and 6th of February, Bionaturis was present at VIV-MEA , the most important animal health evento of the EMA region.

 

Abu Dhabi turned for a few days into a neuralgic animal health center for production animals  for the Middle East and Africa.

Our sales manager, Fran Bascon, event assistant, tells us first-hand impressions.

 

 

1. VIV-MEA is an event indexes in animal health for the zone that concentrates visitors and companies from many countries and places of the world. Which were the aims of the Group Bionaturis in this event?

Our attendance to the event has been a great opportunity for 1) gaining more knowledge and insights of the market in Middle East, 2) consolidate the strategic relations we already have in the territory and 3) finding new synergies. Middle East is a huge market that is demanding and consuming innovative products at a very fast pace (for instance, the use of probiotics for animal feed has grown 600% in the past 5 years). Products with a strong scientific background and a solid development are highly desired and in that sense, Bionaturis has a lot to value to deliver.

In terms of number of European companies in the event, the attendance has been pretty significant. Despite the fact that there is a homologous event in Europe, all the big players were in the event, thus highlighting the importance of this region and the opportunity of entering in that market.

 

2. During the day, took place events about networking  and you had the possibility of meeting several companies from the region, how you value the VIV-MEA event as forum to find new opportunities of business?

The event was the perfect environment to gain first-hand experience of the market in Middle East, their challenges […]

February 21st, 2018|Blog english|Comments Off on Fran Bascón tells us about VIV-MEA 2018,Abu Dhabi.

Bionaturis Leishmaniasis Vaccine Granted in USA

 

This new concession in USA joins the one already obtained by Bionaturis in China last September for the same patent family.

 

Each year 80 million dogs are in danger of developing the disease in the affected areas of Europe and America. Visceral leishmaniasis affects more than 700,000 people worldwide each year, with the dog being the main reservoir of the disease.

 

The granted patent protects the use of the intended vaccine in dogs and humans.

 

Bionaturis goes one step further in the pet market, which according to Euromonitor International represented 93,000 million euros in 2015.

 

The Centro de Desarrollo Tecnologico e Industrial (CDTI) has also granted Bionaturis a non-refundable incentive worth 196,300 euros to support the achievement of a new intermediate milestone in the development of the vaccine.

 

Jerez de la Frontera, February XX, 2018.- The US Patent and Trademark Office (USPTO) has granted the patent for the prevention and treatment of visceral leishmaniasis in both dogs and humans to the vaccine against this disease, which Bionaturis holds the worldwide exclusivity. The lead vaccine program, called internally BNT005, comes originally from the CSIC (Spanish National Council of Research)

 

Currently, BNT005 is the subject of an Evaluation and Options (E&O) agreement with an international sponsor for the exclusive sublicense of the registration and commercialization of BNT005 for use in dogs worldwide, except Argentina and Paraguay, where it has been already licensed for the same purpose to the Argentine laboratory Biotandil.

 

Visceral leishmaniasis affects between 700,000 and 1,000,000 people each year and has a mortality rate of 3%, according to data provided by the World Health Organization (WHO). In Spain, it is estimated that around 300 people suffer each year. It is a tropical disease that is transmitted through the bite of insects. The […]

February 21st, 2018|Blog english, Hechos Relevantes|Comments Off on Bionaturis Leishmaniasis Vaccine Granted in USA

Bionaturis will show its value in BioEurope, Berlín.

From November 6 to 8th, Bionaturis Group will take part in BioEurope 2017, to be held in Berlin this edition, to present its rich portfolio of premium products and services.

2176 biotechnological and pharmaceutical companies come together in this event from November 6th to November 8th, 2017. In total they will put in negotiation on 5108 biotechnological assets in the meetings already agreed between the assistants during two months previous to the event.

2176 biotechnological and pharmaceutical companies will come together in this event where 5108 biotechnological assets will be put in negotiations during the pre-scheduled one to one meetings.

All the business divisions of Bionaturis Group will be represented in this edition.  Juan Jose Infante, Chief of biological developments as part of the Animal Health division, Andoni Cruz, representing the CRO services and Miriam Bastida, showcasing the bioprocessing optimization tools of the CDMO division.

As a partner of choice to bring premium products to the market place, Dr. Infante will meet the world leaders representatives in animal health to follow up the joint on-going initiatives and to open-up new licensing opportunities for co-development.

After the successful participation in BioEurope Spring and having already exceeded the sales figure of the whole previous year, Biobide (CRO division) will be in Berlin in order to strength its relationship with its pharmaceutical and biotechnological network, to set new collaborations, as well as to showcase its new services in zebrafish, being an international reference in this field.

Miriam Bastida will update attendees about the latest of Splittera and Zera, within the CDMO division of bioprocesses, specifically designed to optimize the developments of biological drugs, which presents a global expected market figure worth of 236 billion dollars by 2019.

For more information, visit the official web here.

 

 

November 6th, 2017|Blog english|Comments Off on Bionaturis will show its value in BioEurope, Berlín.

Bionaturis leishmaniasis vaccine patent granted in China

The State Intellectual Property Office (SIPO) of the People’s Republic of China has granted to Bionaturis and CSIC the patent entitled “Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the protein of leishmania infantum with specific immunodominant epitopes “ under the number CN 201280045285. This patent belongs to the original patent family that protects the use and application of the candidate BNT005 for the treatment and prevention of canine visceral leishmaniasis.

BNT005 is currently subject to an Evaluation and Option (E&O) agreement with an international sponsor for the exclusive worldwide license to register and commercialize this vaccine against canine leishmaniasis in all countries except Argentina and Paraguay.

At the same time, BNT005 is also subject to an exclusive license agreement for registration, development, manufacture and marketing with Biotandil for the Argentine and Paraguayan markets. Under the agreement, Bionaturis will receive 50% of the profits from the commercial exploitation of the vaccine within the territory.

For the official disclosing Click here (only in Spanish)

September 21st, 2017|Blog english|Comments Off on Bionaturis leishmaniasis vaccine patent granted in China

Bionaturis Group takes part in two events in USA in June

Bionaturis Group representatives will showcase the biotechnological group offer in two relevant events in USA in June: the World Preclinical Congress (Boston) and the Bio International Convention (San Diego).

Biobide’s Management Director, Arantza Muriana, will take part in the first one, attending the programme Predicting Drug Toxicity and she will present the scientific poster titled “Toxicity Profiling Using a Battery of Assays in Zebrafish Embryos Including Teratogenicity, Behavior, Cardiotoxicity, Ototoxicity and Hepatotoxicity“ on 13 and 14th, June. “Our experience and broad offer of assays with zebrafish as animal model as well as the importance that USA has for Biobide –our subsidiary is located in Maryland and we are included in the exclusive group of Spanish companies that work with the NIEHS- turn the World Preclinical Congress into an essential event to consolidate the relationships with our current customers and stablish new ones”, Arantza Muriana has stated.

The World Preclinical Congress will tackle the latest trends and technologies related to the drug discovery. It is a multidisciplinary event attended by experts from different sectors such as chemical, biological and pharmaceutical ones, among others.

To arrange a meeting with Biobide in Boston, please, write to clientes@biobide.es

For further information about the World Preclinical Congress, visit its official website.

Attending the Bio International Convention once again

Bionaturis Group will not miss its annual appointment with the global biotechnology taking part in the Bio International Convention, considered the most relevant event in the biotechnological sector worldwide. From 19 to 22th, June, Biobide’s General Manager, Andoni Cruz, and Bionaturis CSO, Juan Jose Infante, will showcase the broad offer of premium products and services for Human and Animal Health in this relevant forum in Bionaturis Group schedule.

Bionaturis Group arrives to this international forum after signing relevant license […]

June 8th, 2017|Blog english, congress|Comments Off on Bionaturis Group takes part in two events in USA in June

Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis vaccine with the company Biotandil for Argentina and Paraguay
According to the terms of the license, Bionaturis will receive 50% of the profits resulting of the commercialization.
The immunization of these animals –the main reservoir of this neglected tropical disease- is crucial to avoid zoonosis episodes

 

Jerez de la Frontera, April 25, 2017.  Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis lead vaccine (BNT005) with the company Laboratorio Biologico de Tandil (Biotandil) for Argentina and Paraguay as the Territory. According to the terms of the license, Biotandil will be responsible for the manufacturing, development, registration, and commercialization of the vaccine in the territory. In exchange Bionaturis will receive 50% of the profits resulting of the commercialization.

Visceral Canine Leishmaniasis is a so called neglected tropical disease transmitted by the bite of the phlebotomine sandfly that acts as a vector. One of its main reservoir –spread through the Mediterranean countries and LATAM – are dogs, and therefore their immunization is crucial to minimize zoonosis episodes. According to WHO, in humans between 700.000 and 1.000.000 new cases, with 3% of deaths, are registered annually worldwide. In Argentina, there is in place a Leishmaniasis National Programme led to track its progress in the country and promoting control and eradication measures.

“This specific license of our Leishmaniasis vaccine candidate means a significant milestone because LATAM is one of the most affected regions by this disease, being recorded a steady growth in Argentine and Paraguay lately. Besides, getting the market authorization in Argentina could pave the way for its registration in other Latin American markets”, the chief of biological developments in Bionaturis, Juan Jose Infante, […]

April 25th, 2017|Blog english, Press Releases|Comments Off on Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

Ojer Pharma and Bionaturis sign a registration and commercialization agreement to market MUPIPET® in Europe

Ojer Pharma and Bionaturis have signed a co-development, registration, and commercialization agreement to market Mupipet® in Europe, the first antibiotic with a bioadhesive and transparent formulation registered in Europe to treat skin bacterial infections in companion animals.

Mupipet® will be registered as a prescription veterinary drug for the topical treatment of skin bacterial infections in companion animals -such as pyoderma- being its main competitive advantage its cutting-edge formulation, developed and patented by the pharmaceutical company Ojer Pharma. Mupipet® is formulated in a transparent bioadhesive film, with acts as a controlled release matrix, ensuring the permanence of the active substance at the site of action and, as a result, a higher efficacy. This system makes unnecessary the use of dressing pads to cover the affected area and reduces product removal accidentally or by scratching and licking, which allows the treatment permanence for at least 12 hours. “The results of field studies already performed demonstrate that Mupipet® has better safety and efficacy profile that other reference products”, Carlos Gonzalez, General Manager at Ojer Pharma, has stated. “The isolation provided by this bioadhesive lipogel formulation reduces the risk of infections and protects the skin against external agents, as well as ensures the permanence of the product in the skin until the infection has been completely removed, with an excellent skin tolerability and non-irritant”, he has added.

“With this agreement, Mupipet® enriches our Premium portfolio for pets, in this case, under the category of prescription drugs. Due to its features, Mupipet® is a unique patent-protected product with outstanding competitive advantages versus other alternatives, and fitting our portfolio requirements. Besides, we expect this strategic agreement consolidates the relationship with Ojer Pharma to start the development of new innovative products. The transparent bioadhesive […]

March 29th, 2017|Blog english|Comments Off on Ojer Pharma and Bionaturis sign a registration and commercialization agreement to market MUPIPET® in Europe

Bionaturis showcases in the European Animal Health Investment Forum in London

Bionaturis will attend the European Animal Health Investment, to be held in London. This event is becoming a benchmark for the Animal Health space, a sector showing a steady growth based on solid drivers globally and which is drawing the attention of investors and analysts all over the world. The event will gather more than 200 hundred experts in the field –including C-level executives of multinational companies, emerging ones, services providers, and investors- surpassing 2016 figures.

As a partner of choice for the development of Premium products for Animal Health, Bionaturis delegates have already arranged a full schedule of business meetings with on-going and potential partners and customers. The main goal of the company in this new edition is to consolidate existing business relationships, plus setting new licenses and strategic collaboration agreements, among others. By a B2B business model, those alliances are crucial for Bionaturis to continue growing and consolidating its position in this sector.

Besides the partnering one-to-one meetings, the event will be a discussion forum on the hot-topics in the sector, such as the emerging markets, the new areas of interest in innovation, the global trend of reducing the use of traditional antibiotics in livestock or the steady growing pace of the pets market. In this sense, Bionaturis will have the opportunity to showcase its ever growing portfolio of outstanding products and services addressed to meet these needs and trends, offering premium alternatives for both Food Production Animals (FPAs) and pets.

You can follow the event in Social Media with the hashtag #AHInvestEurope.

For further information about the event

About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT […]

February 9th, 2017|Blog english|Comments Off on Bionaturis showcases in the European Animal Health Investment Forum in London

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR